Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Fiche publication
Date publication
octobre 2018
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe, Pr PETIT Thierry, Dr DESMOULINS Isabelle
Tous les auteurs :
Cabel L, Carton M, Cheaib B, Pierga JY, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Pérol D, Simon G, Lerebours F
Lien Pubmed
Résumé
HER2-negative metastatic breast cancer (MBC) is a common setting in which chemotherapy could be effective even in later lines of treatment. Oral etoposide has demonstrated clinical activity in this setting in small-scale studies, but its efficacy has not been compared to that of other chemotherapy regimens.
Mots clés
Etoposide, Metastatic breast cancer, Oral drug
Référence
Breast Cancer Res. Treat.. 2018 Oct 24;: